Income Taxes (Details Narrative) - USD ($)	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Pretax losses arising from domestic operations	$ 1,274,619	$ (8,025,582)	$ (8,040,033)
Pretax losses arising from foreign operations	1,276,036	$ 528,741	$ 1,450,244
Generex Biotechnology Corporation
NOL carryforwards, expiring through 2033	202,000,000
Generex Pharmaceuticals, Inc
NOL carryforwards, expiring through 2033	44,000,000
Antigen Express, Inc
NOL carryforwards, expiring through 2033	$ 25,000,000

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Name:	us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant